Osprey Medical
(ASX:OSP) has released its latest cash flow report, showing quarter on quarter and year on year sales growth for its dye saving technologies.
Unit sales for Osprey’s DyeVert system were up 34 percent for Q3 compared to Q2 of this year, with the company also posting a 239 percent increase on Q3 2015.
The number of US hospitals on the company’s books increased for quarter, with the company indicating a strong pipeline of new hospitals at the evaluation stage was also building.
Following an oversubscribed capital raising the company has begun aggressively scaling up its US sales force, as it seeks to increase its footprint in the US market.
Osprey Medical reported a net loss of $8.2 million at 30 June 2016.
